MannKind says it is confident sales of its inhaled insulin product Afrezza - commercialised by Sanofi - will pick up after disappointing growth since launch.
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
Canadian company Generex Biotechnology has stolen a march on its
larger rivals in the pharmaceutical industry by winning regulatory
approval for the world's first non-injectable insulin formulation,
reports Phil Taylor.
MannKind has presented new data on its inhaled insulin product that
suggest it may not only make dosing the drug more convenient, but
also improve efficacy compared to insulin injections.
Bristol-Myers Squibb has taken another step towards building a
franchise in insulin therapy by licensing an inhaled version of the
drug from QDose for $30m.